drugset
drugset / Trial / NCT06065462

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT06065462 ↗

Phase 1/2 Recruiting 21 enrolled M.D. Anderson Cancer Center GSK Pharma · collabLixte · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

Timeline

Start
2023-11-10
Primary completion
2027-10-01
Completion
2027-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dostarlimab Monoclonal antibody — Intravenous
Subject LB-100 Small molecule — Intravenous

Indications

ovarian clear cell cancer